Floatz logo

Teplizumab-MZWV

Breast Cancer, Estrogen Receptor-Positive

Guangzhou Women and Children's Medical Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Breast Cancer, Estrogen Receptor-Positive cohort.

Asset / SponsorPhaseRating
T-Dxd
Guangzhou Women and Children's Medical Center
Phase 2CCC

Same molecule, other indications

Teplizumab-MZWV is also rated in:

HER2 Low Breast CancerDormant
CCC
Indicative ·
53 / 100
View asset →
non-small cell lung carcinomaDormant
D
Indicative ·
26 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →